We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

102 hedge funds and large institutions have $555M invested in BioCryst Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

10% more call options, than puts

Call options by funds: $4.45M | Put options by funds: $4.04M

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1% less funds holding

Funds holding: 103 → 102 (-1)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

18% less capital invested

Capital invested by funds: $677M → $555M (-$123M)

Holders
102
Holders Change
-1
Holders Change %
-0.97%
% of All Funds
2.96%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
21
Increased
34
Reduced
28
Closed
22
Calls
$4.45M
Puts
$4.04M
Net Calls
+$413K
Net Calls Change
-$6.73M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$47.4M
2
Northern Trust
Northern Trust
Illinois
+$7.39M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$6.25M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$2.82M
5
GC
Guggenheim Capital
Illinois
+$2.48M

Top Sellers

Rank Fund Capital Flow
1
BIM
Bogle Investment Management
Massachusetts
-$7.98M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.04M
3
Two Sigma Investments
Two Sigma Investments
New York
-$3.29M
4
Marshall Wace
Marshall Wace
United Kingdom
-$2.79M
5
Morgan Stanley
Morgan Stanley
New York
-$2.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.66M +$245K +20,000 +13%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$1.41M – – –
ARTA
28
A.R.T. Advisors
New York
$1.4M +$434K +35,417 +33%
BG
29
BlackRock Group
United Kingdom
$1.38M +$13.4K +1,095 +0.8%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$1.26M +$16.3K +1,334 +1%
AllianceBernstein
31
AllianceBernstein
Tennessee
$1.05M +$24.5K +2,000 +2%
USAA
32
United Services Automobile Association
Texas
$1.01M – – –
Macquarie Group
33
Macquarie Group
Australia
$964K +$790K +64,451 +189%
TA
34
Teachers Advisors
New York
$960K – – –
Citadel Advisors
35
Citadel Advisors
Florida
$914K -$32.6K -2,659 -3%
FSA
36
Franklin Street Advisors
North Carolina
$910K – – –
NPC
37
National Planning Corporation
California
$871K +$834K +68,050 New
EI
38
EAM Investors
California
$838K – – –
SIM
39
Spark Investment Management
New York
$764K -$412K -33,600 -30%
DCM
40
DAFNA Capital Management
California
$747K +$936K +76,400 New
PP
41
PDT Partners
New York
$689K -$368K -30,040 -30%
RFC
42
Russell Frank Company
Washington
$680K – – –
U
43
UBS
Switzerland
$668K -$4.9K -400 -0.6%
CS
44
Credit Suisse
Switzerland
$666K +$180K +14,684 +27%
ProShare Advisors
45
ProShare Advisors
Maryland
$633K -$145K -11,866 -15%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$627K -$29.2K -2,380 -4%
Swiss National Bank
47
Swiss National Bank
Switzerland
$625K -$134K -10,900 -15%
BlackRock
48
BlackRock
New York
$622K -$52.7K -4,300 -6%
MLICM
49
Metropolitan Life Insurance Company (MetLife)
New York
$535K – – –
GCP
50
GSA Capital Partners
United Kingdom
$535K +$670K +54,674 New
1
2
3 4 5

BCRX Hedge Fund Activity: Q3 2014 in Review

102 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2014, worth a combined $555M — down 18% from $677M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 34 added.

The largest buyer was RA Capital Management, adding an estimated $47.4M. The largest seller was Bogle Investment Management, exiting entirely with an estimated $7.98M sold.

  • 102 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2014, down from 103 in Q2 2014.
  • Funds reported $555M of BioCryst Pharmaceuticals stock for Q3 2014, down 18% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2014 and 22 closed out, a net change of -1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2014 was RA Capital Management, an estimated $47.4M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2014 was Bogle Investment Management, an estimated $7.98M sold.

Based on aggregated 13F filings for Q3 2014.